GLP-1 Drugs and Alcohol: Why Patients Drink Less on Tirzepatide and Semaglutide, What the Trials Show, and the Safety Rules That Still Apply

What patients report

Among the most consistent things patients on GLP-1 medications say, after reduced hunger, is that they lost interest in alcohol. A glass of wine tastes less appealing, two drinks feel like four, the evening ritual fades. Surveys of patients on semaglutide and tirzepatide report reduced drinking in a large minority to a majority, and the phenomenon is common enough that "Ozempic cured my drinking" has become a genre of testimonial. Testimonials are not evidence, but in this case the evidence has begun to arrive.

The randomized trial

The first randomized, placebo-controlled trial of a modern GLP-1 agonist for drinking was published in JAMA Psychiatry in February 2025. Hendershot and colleagues randomized 48 adults with alcohol use disorder who were not seeking treatment to low-dose semaglutide (escalated to 1 mg) or placebo for nine weeks. Semaglutide reduced the amount consumed per drinking day in a laboratory self-administration session, reduced drinks per drinking day in the natural environment, and reduced craving, with effect sizes the authors described as medium to large for a nine-week trial at sub-maximal doses. It did not significantly reduce the number of drinking days. Among participants who smoked, cigarettes per day also fell. The trial was small and short, the doses were below the weight-management dose, and it enrolled people who were not trying to quit; it establishes that the effect exists, not how large it is over a year or in treatment-seeking populations.

An earlier trial of exenatide, a first-generation GLP-1 agonist, published in JCI Insight in 2022, found no overall effect on heavy drinking days over 26 weeks but a reduction in the subgroup with obesity, and brain imaging showed reduced alcohol-cue reactivity in reward regions. Larger trials of semaglutide in alcohol use disorder are under way.

The cohort studies

Two large observational studies point in the same direction. Wang and colleagues, in Nature Communications in 2024, used a database of more than 80,000 patients with obesity and found that semaglutide was associated with a 50 to 56% lower risk of a new alcohol use disorder diagnosis and of recurrence in those with an existing diagnosis, compared with other anti-obesity medications, over 12 months. Lähteenvuo and colleagues, in JAMA Psychiatry in 2025, followed about 228,000 people with alcohol use disorder in Sweden and found that periods of semaglutide or liraglutide use were associated with 36% and 28% lower risk of alcohol-related hospitalization respectively, larger reductions than seen with the approved alcohol-use-disorder medications naltrexone, acamprosate and disulfiram in the same cohort. Observational studies cannot exclude confounding, and people prescribed a GLP-1 differ from those who are not in ways that affect drinking; the consistency between the cohorts and the trial is what makes the signal credible.

The mechanism

GLP-1 receptors are expressed in the brain's reward circuitry, including the ventral tegmental area and nucleus accumbens, and in the hindbrain nuclei that project to them. In rodents, GLP-1 agonists reduce alcohol intake, reduce the dopamine release in the nucleus accumbens that alcohol normally produces, reduce alcohol-seeking and relapse-like behaviour, and blunt the rewarding effects of nicotine, cocaine and amphetamine. The same signalling that reduces the reward value of food appears to reduce the reward value of alcohol. Semaglutide and tirzepatide cross into the brain to a limited degree but act on circumventricular and hindbrain regions with direct access; the details are still being worked out. The mechanism is plausible and supported by imaging in humans showing reduced cue reactivity.

A second, simpler mechanism also operates: slowed gastric emptying and reduced appetite make alcohol less pleasant. Patients report that drinks sit heavily, that they feel intoxicated faster on a reduced stomach, and that nausea follows.

What is not established

No GLP-1 medication is approved for alcohol use disorder in any country. No trial has tested tirzepatide for drinking, although patient reports and the shared mechanism make an effect likely. The randomized evidence is a single nine-week trial of 48 people at low doses. The effect on drinking days, as opposed to drinks per occasion, was not significant in that trial. Whether the effect persists, whether it depends on weight loss, and whether it extends to people with severe dependence who are trying to quit are open questions. A patient with a drinking problem should not treat a GLP-1 prescribed for weight as a substitute for evaluation and treatment, and a clinician should not prescribe one for drinking outside a trial. The honest framing is that reduced drinking is a common and increasingly well-documented side effect, and a promising research direction, not an indication.

Drinking on a GLP-1: the safety rules

Neither label prohibits alcohol, but four warnings in the labels interact with it.

Hypoglycemia. Alcohol suppresses hepatic glucose output. In a patient taking insulin or a sulfonylurea alongside a GLP-1, that adds to the drugs' glucose-lowering and can produce serious hypoglycemia hours after drinking, including overnight. Patients on those medications should not drink on an empty stomach, should check glucose before bed after drinking, and should discuss dose adjustment with their prescriber.

Pancreatitis. Alcohol is the second most common cause of acute pancreatitis; GLP-1 medications carry a pancreatitis warning. The combined risk is not quantified but is additive in principle. Heavy drinking on a GLP-1 is unwise for this reason alone, and severe abdominal pain after drinking needs same-day evaluation.

Dehydration. Nausea, vomiting and diarrhea in the escalation weeks already deplete fluid; alcohol is a diuretic. The labels warn about acute kidney injury from dehydration. Alternate drinks with water and avoid alcohol in the two days after a dose increase.

Faster intoxication and worse hangovers. Reduced intake means alcohol is absorbed on a near-empty stomach; slowed emptying holds it in the stomach and then releases it. Patients consistently report that their tolerance has fallen. Drink less than you used to and expect it to hit harder.

There is also the arithmetic. Alcohol is 7 calories per gram and disinhibits eating; a patient losing weight who drinks moderately is spending a meaningful share of a reduced calorie budget on it. Many patients find the drug makes that choice for them.

What to tell your prescriber

That you drink, how much, and whether it has changed. Reduced drinking is worth recording because it may matter for future indications and because it helps the clinician interpret weight loss. Increased drinking, or drinking to manage nausea or low mood, is a warning sign worth raising. And a patient who was drinking heavily before starting and stops abruptly because the drug removed the desire should know that alcohol withdrawal in a dependent person can be dangerous, and should tell a clinician rather than assume the drug has handled it.

Where this is going

Larger and longer trials of semaglutide in alcohol use disorder, and trials in other addictions including smoking and opioid use, are in progress. If they confirm the 2025 results at scale, GLP-1 medications may become the first new class of drugs for alcohol use disorder in two decades. For now, the reduced drinking most patients notice is a real pharmacological effect with a plausible mechanism, a supportive but limited evidence base, and safety rules that still apply.

Sources

1. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2025;82(4):395-405.
2. Wang W, Volkow ND, Berger NA, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun 2024;15:4548.
3. Lähteenvuo M, Tiihonen J, Solismaa A, et al. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry 2025;82(1):94-98.
4. Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight 2022;7:e159863.
5. Jerlhag E. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front Pharmacol 2023;14:1063033.
6. Zepbound and Wegovy prescribing information (hypoglycemia, pancreatitis, dehydration warnings).

Citations are to primary sources (peer-reviewed trials, FDA labeling and announcements, and provider pricing pages). See our sources policy and corrections log.